Abstracts tagged "Autoantibodies and lupus nephritis"

Abstract Number: 2064 • 2016 ACR/ARHP Annual Meeting
Blood and Kidney Molecular Profiles Distinguish Subjects with Lupus Nephritis from Other Kidney Disorders
Matteo Cesaroni¹, Jarrat Jordan¹, Marc Chevrier², Alan Perlman³, James M. Chevalier⁴, Thomas Parker³, Daniel Levine³, Surya V. Seshan⁵, Anna Gong⁶, Takahiro Sato¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³The Rogosin Institute,New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY, ⁴Nephrology, The Rogosin Institute New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, ⁵Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁶The Rogosin Institute,New York Presbyterian Hospital-Weill Medical College of Cornell University, new york, NY
Background/Purpose: Kidney biopsy remains the gold standard for diagnosis and staging of Lupus Nephritis (LN). Although kidney biopsies are commonly performed in the clinical setting,…
Abstract Number: 592 • 2013 ACR/ARHP Annual Meeting
Analysis Of Relationship Between Clinical Manifestations and Autoantibody Profile In ISN/RPS Class V Lupus Nephritis
Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hisashi Yamanaka, Yasuhiro Katsumata, Kae Takagi, Hirotaka Kaneko, Hisae Ichida, Yuko Ota, Hidenaga Kawasumi, Sayumi Baba, Yuko Okamoto and Sayuri Kataoka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Clinical manifestations, pathohistology and treatment strategy are different between International Society of Nephrology/Renal Pathology Society (ISN /RPS) class III/IV and class V Lupus Nephritis…
Abstract Number: 581 • 2013 ACR/ARHP Annual Meeting
Predictive Value Of The Autoantibody Triad Of Anti-Ro, Anti-Sm and Anti-RNP For The Future Development Of Lupus Nephritis
Natasha Jordan and David D'Cruz, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Autoantibody production against nuclear components is a characteristic feature of SLE. Autoantibody clustering may provide a valuable tool to differentiate between clinical subsets and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].